The Invisible Struggle: New Hope for Severe Skin Disease

Hidradenitis Suppurativa (HS) is a chronic, painful, and often stigmatised inflammatory skin disease. Because it affects areas of the body that are rarely discussed, it is frequently an "invisible struggle" for those living with it.

Avalo Therapeutics has brought a new beacon of hope with its Phase 2 LOTUS trial for abdakibart. The trial met its primary endpoints at both studied doses, showing a significant reduction in the severity of the disease for adults with moderate to severe HS.

For patients who have exhausted current treatment options, the success of this trial represents more than just a medical milestone—it is a validation of their struggle and a step toward a life with less pain and more confidence.

Key Facts

• Drug: Abdakibart [StockTitan/SEC].
• Trial: LOTUS Phase 2 [StockTitan/SEC].
• Outcome: Primary endpoints met at both studied doses [StockTitan/SEC].

Why This Matters

HS is often misdiagnosed as acne or boils, leading to years of ineffective treatment and psychological distress. The lack of targeted therapies has left a huge gap in dermatological care, which abdakibart aims to fill by treating the underlying inflammation rather than just the surface symptoms.

What We Don't Know Yet

As a Phase 2 trial, the sample size is smaller than a pivotal Phase 3 study. Long-term safety and "real-world" efficacy still need to be proven before the drug can be widely prescribed to the general public.

Sources: StockTitan
Published 2026-05-06 · Category: Health & Medicine